Page last updated: 2024-10-31

naratriptan and Abnormalities, Drug-Induced

naratriptan has been researched along with Abnormalities, Drug-Induced in 1 studies

naratriptan: structure given in first source

Abnormalities, Drug-Induced: Congenital abnormalities caused by medicinal substances or drugs of abuse given to or taken by the mother, or to which she is inadvertently exposed during the manufacture of such substances. The concept excludes abnormalities resulting from exposure to non-medicinal chemicals in the environment.

Research Excerpts

ExcerptRelevanceReference
"Using the Marketscan database, the risk of major birth defects was ascertained in live-born infants whose birth mothers were exposed to sumatriptan, naratriptan, or sumatriptan/naproxen during pregnancy."3.88Use of existing electronic health care databases to evaluate medication safety in pregnancy: Triptan exposure in pregnancy as a case study. ( Bollinger, L; Cangialose, C; Chia, V; Mikol, DD; Xue, F; Yusuf, A, 2018)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Yusuf, A1
Chia, V1
Xue, F1
Mikol, DD1
Bollinger, L1
Cangialose, C1

Other Studies

1 other study available for naratriptan and Abnormalities, Drug-Induced

ArticleYear
Use of existing electronic health care databases to evaluate medication safety in pregnancy: Triptan exposure in pregnancy as a case study.
    Pharmacoepidemiology and drug safety, 2018, Volume: 27, Issue:12

    Topics: Abnormalities, Drug-Induced; Administrative Claims, Healthcare; Adolescent; Adult; Databases, Factua

2018